PEG-Epo 75 mcg/0.3 ml
Pegylated Erythropoietin
Category: IV/SC Injection
Manufacturer: Incepta Pharmaceuticals Ltd.
Allopathic
MFG. Licence No. Biological
193
MFG. Licence No. Non-Biological
108
Address
Zirabo, Savar, Dhaka Dewan Idris Road, Bara Rangamatia
Price: 5500.0 ৳
0.3 ml pre-filled syringe
Medicine Selling service is not available yet.
Related Medicines
Pegylated erythropoietin is indicated for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis and patients, not on dialysis.It is not indicated for use:
In the treatment of anemia due to cancer chemotherapy.
As a substitute for RBC transfusions in patients who require immediate correction of anemia.
Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism
Increased mortality and/or tumor progression in patients with cancer
Hypertension
Seizures
Pure red cell aplasia
Serious allergic reactions
Using ESA to target a hemoglobin level of >11 g/dL increase the rate of serious adverse cardiovascular reactions. It should be used with caution in patients with co-existant cardiovascular disease, stroke, seizure etc.
Control hypertension prior to initiating of and during treatment with it
Monitoring of patients for the change in seizure frequency or premonitory symptoms.
If severe anemia and low reticulocyte count develop during the treatment, withhold it and evaluate patients for neutralizing antibodies to erythropoietin
Pegylated Erythropoietin overdosage can elevate hemoglobin levels above the desired level, which should be managed with discontinuation or reduction of Pegylated Erythropoietin dosage and/or with phlebotomy. Cases of severe hypertension have been observed following overdose with ESAs.
Store at 2°C to 8°C at the refrigerator. Protect from light. Do not shake the syringe. Keep out of the reach of children.
Drugs for Haemolytic Hypoplastic & Renal Anemia
Pegylated erythropoietin is an erythropoietin receptor activator with greater activity in vivo as well as increased half-life, in contrast to erythropoietin. It differs from erythropoietin through the integration of an amide bond between the N-terminal amino group or the ε-amino group of any lysine present in erythropoietin, predominantly Lys52 and Lys45 and Pegylated Erythropoietin (PEG).
Pregnancy Category C. It is not known whether it is excreted into human breast milk. Because many drugs are excreted in human milk, caution should be exercised when it is administered to a nursing woman.Evaluation of Iron stores: Supplementary iron therapy is recommended for all patients with serum ferritin values below 100 mcg/L or with transferrin saturation below 20%. To ensure effective erythropoiesis, iron status has to be evaluated for all patients prior to and during treatment.
Samm Care